House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Endocrinology

Vitamin D for the prevention of disease

Endocrine Society · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The Endocrine Society disease-prevention guideline separates ordinary dietary requirements, selected groups who may benefit from empiric supplementation, and the limited value of routine serum screening. Recommendations are generally conditional and apply to people without a pre-existing treatment or testing indication. They should not be converted into a universal deficiency-treatment target or a high-dose regimen.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Apply prevention guidance to the intended population

  • Use these recommendations for disease prevention in people without an established indication for vitamin D treatment or testing. They do not remove a clinical indication to investigate problems such as hypocalcaemia. [1]
  • In otherwise healthy adults, the panel suggests against routine testing or dose adjustment driven by an assumed disease-prevention serum target. Outcome-specific beneficial concentrations have not been established. [1]

Differentiate childhood supplementation from routine adult use

  • For children and adolescents aged 1–18 years, the panel suggests empiric supplementation to prevent nutritional rickets and potentially reduce respiratory infections. This is a conditional recommendation, and potential infection benefit is not presented as certain. [1]
  • Empiric intake can come from fortified foods, vitamin preparations or a daily supplement. The trial-dose range reported in the guideline is evidence description, not a single universal prescribed dose. [1]
  • For generally healthy nonpregnant adults younger than 50, the panel suggests against empiric supplementation above the recommended dietary intake. It still advises the usual daily allowance of 600 IU rather than avoidance of vitamin D intake altogether. [1]
  • In generally healthy nonpregnant adults younger than 50 without a separate indication, the panel suggests against routine serum vitamin D testing to decide whether to supplement or adjust the dose. [1]

Use age-specific prevention recommendations

  • For generally healthy adults aged 50–74, the panel suggests against routine supplementation beyond standard dietary intake. The cited allowance is 600 IU daily at ages 50–70 and 800 IU daily above 70. [1]
  • For generally healthy people aged 50–74, the panel also suggests against routine vitamin D testing. The absence of an established outcome-based threshold limits test-driven supplementation in this population. [1]
  • For adults aged 75 and older, the panel suggests empiric supplementation because it may reduce mortality. Prefer daily lower-dose intake over intermittent larger doses. [1]
  • The recommendation to supplement older adults does not require routine serum testing. In generally healthy adults aged 75 and older without a separate testing indication, the panel suggests against routine measurement. [1]

Retain the conditional and adjunctive nature of benefit

  • During pregnancy, the panel suggests empiric supplementation for potential reductions in pre-eclampsia, fetal or neonatal death, preterm birth and small-for-gestational-age birth. The recommendation draws on trials in otherwise healthy pregnant individuals. [1]
  • Routine serum testing is not suggested in otherwise healthy pregnancy without a separate indication. The guideline does not establish a pregnancy-outcome target concentration to guide screening or follow-up dosing. [1]
  • For adults with high-risk prediabetes, the panel suggests vitamin D in addition to lifestyle change to lower progression risk. The supporting trials primarily enrolled people with impaired glucose tolerance or two or three glycaemic prediabetes criteria. Lifestyle intervention remains routine care. [1]
  • Interpret the prediabetes recommendation in its studied population: trials mainly enrolled adults with impaired glucose tolerance or multiple glycaemic criteria for prediabetes, rather than proving the same benefit in every low-risk individual. [1]

Avoid routine screening and prefer daily dosing when indicated

  • For nonpregnant adults aged at least 50 who have an indication for treatment or supplementation, the panel suggests daily lower-dose treatment instead of intermittent higher-dose treatment. It identified no corresponding evidence for people below 50. [1]
  • The panel suggests against routine serum screening in healthy adults, including generally healthy adults with dark complexion or obesity when no separate testing indication exists. Skin colour or obesity alone should not be treated as an automatic indication under this prevention guideline. [1]

Limitations and use

  • The guideline addresses disease prevention, not a full replacement protocol for established vitamin D deficiency, hypocalcaemia or another specific clinical indication.
  • Reported trial dose ranges and weighted averages are not presented here as prescribed doses; no universal prevention target concentration was established.
  • The recommendations do not establish an individual regimen for every comorbidity or an India-specific product or prescribing schedule.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Vitamin D for the prevention of disease

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
Endocrine Society
First published
3 June 2024
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Apply prevention guidance to the intended population
  • Differentiate childhood supplementation from routine adult use
  • Use age-specific prevention recommendations
  • Retain the conditional and adjunctive nature of benefit
  • Avoid routine screening and prefer daily dosing when indicated
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House